Q1 2026 earnings call recap: guidance cut on Middle East headwinds, ddPCR/QX700 momentum, margins & FCF outlook—read key takeaways.
ORLANDO, Fla. — The Central Florida Expressway Authority is using first-of-its-kind technology with Route Reports, monitoring 125 miles of toll roads. Central Florida Expressway Authority is using the ...
Life science company Bio-Rad Laboratories has extended its range of recombinant monoclonal anti -idiotypic antibodies. The ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the ...
Hosted on MSN
Citigroup downgrades Bio-Rad Laboratories (BIO)
Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...
New drug manufacturer Neion Bio has emerged from stealth after incubating a novel way to cook up biologic drugs. After its founding two years ago, the company is cracking open a multi-product ...
Rad Pow er Bikes, once the dominant force in North America’s direct-to-consumer e-bike boom, has officially found a new home. Life Electric Vehicles Holdings (Life EV) announced this week that it has ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Rivian goes to great lengths to prove what its electric vehicles are ...
This is read by an automated voice. Please report any issues or inconsistencies here. AI platform-led structure to fuel vertical expansion, future acquisitions and the launch of two standalone ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results